Table 1 The top 15 identified drug-pathway association pairs on CCLE data set to L2,1-iPaD and iPaD methods
From: Identifying drug-pathway association pairs based on L2,1-integrative penalized matrix decomposition
Drug | KEGG pathway | L 2, 1-iPaD | iPaD | Validated? |
|---|---|---|---|---|
Sorafenib | Calcium signaling pathway | 0 | 5.79E-04 | Yes |
Panobinostat | Pancreatic cancer | 0 | 6.07E-04 | No |
LBW242 | Chronic myeloid leukemia | 2.80E-44 | 1.34E-10 | No |
Nutlin-3 | Chronic myeloid leukemia | 1.74E-43 | 4.82E-16 | Yes |
L-685458 | Chronic myeloid leukemia | 4.33E-43 | 3.20E-31 | No |
17-AAG | Chronic myeloid leukemia | 9.46E-43 | 2.79E-20 | No |
AZD0530 | Colorectal cancer | 1.62E-41 | 3.05E-07 | No |
PD-0332991 | Chronic myeloid leukemia | 6.93E-41 | 1.38E-09 | Yes |
PHA-665752 | Chronic myeloid leukemia | 1.09E-40 | 1.97E-20 | No |
Paclitaxel | Chronic myeloid leukemia | 2.14E-38 | 2.52E-16 | No |
AZD0530 | Chronic myeloid leukemia | 7.12E-38 | 5.12E-13 | Yes |
ZD-6474 | Chronic myeloid leukemia | 1.62E-21 | 1.23E-11 | No |
AZD0530 | ErbB signaling pathway | 4.41E-16 | 2.81E-05 | Yes |
RAF265 | ECM-receptor interaction | 1.26E-15 | 0 | No |
Erlotinib | Chronic myeloid leukemia | 5.69E-15 | 1.98E-11 | Yes |